Leerink Partnrs Has Negative Outlook for AbbVie Q3 Earnings

Key Points

• Leerink Partners has significantly downgraded its Q3 2025 earnings per share estimate for AbbVie from $3.34 to $1.84, indicating a negative outlook for the company.
• Despite this downgrade, several other brokerages have maintained positive ratings, with Bank of America raising its price target for AbbVie from $220.00 to $251.00.
• AbbVie announced a quarterly dividend of $1.64 per share, with a dividend yield of 2.9%, and a current dividend payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of AbbVie in a report issued on Monday, October 13th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $1.84 per share for the quarter, down from their prior forecast of $3.34. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie's FY2025 earnings at $10.54 EPS.

Several other brokerages also recently issued reports on ABBV. Citigroup restated a "neutral" rating on shares of AbbVie in a report on Monday. Bank of America lifted their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Guggenheim raised their price objective on shares of AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Daiwa Capital Markets upgraded shares of AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price objective on the stock in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on AbbVie from $200.00 to $235.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average target price of $231.90.

AbbVie Stock Performance

Shares of AbbVie stock opened at $226.31 on Thursday. The company has a market capitalization of $399.80 billion, a PE ratio of 107.77, a PEG ratio of 1.48 and a beta of 0.51. AbbVie has a 12 month low of $163.81 and a 12 month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The stock's fifty day simple moving average is $216.72 and its 200 day simple moving average is $197.32.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.65 earnings per share.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 2.9%. AbbVie's dividend payout ratio (DPR) is currently 312.38%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.25% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ABBV. Ellenbecker Investment Group lifted its holdings in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock worth $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its stake in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock valued at $3,562,000 after purchasing an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC increased its stake in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock valued at $4,066,000 after purchasing an additional 45 shares during the last quarter. Hobart Private Capital LLC increased its stake in shares of AbbVie by 4.4% in the 3rd quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock valued at $261,000 after purchasing an additional 48 shares during the last quarter. Finally, Rise Advisors LLC lifted its holdings in shares of AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company's stock worth $336,000 after acquiring an additional 48 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.